52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

AI BRIEFING

• ⬤ 29% of patients in the 18 μg/kg arm achieved new SALT Score ≤20 from week 36 to week 52
• ⬤ 31% of patients in the 24 μg/kg arm achieved new SALT Score ≤20 from week 36 to week 52
• ⬤ Increasing proportions of patients achieved clinically meaningful hair growth thresholds across numerous SALT measures